{"id":"W4377093422","doi":"10.1161/circheartfailure.122.009837","title":"Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials","year":2023,"lang":"en","type":"article","venue":"Circulation Heart Failure","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ted Rogers Centre for Heart Research","funders":"National Heart, Lung, and Blood Institute; Relypsa; Vifor Pharma; Impulse Dynamics; Intercept Pharmaceuticals; Prothena; Ironwood Pharmaceuticals, Incorporated; National Institutes of Health; Dexcom; Regeneron Pharmaceuticals; Emory University; Boston Scientific Corporation; University of Pittsburgh; United Therapeutics Corporation; Eli Lilly and Company; U.S. Department of Defense; Sanofi; National Institute on Aging; CSL Behring; Bristol-Myers Squibb; Allergan; AstraZeneca; Edwards Lifesciences; Amgen; Pfizer; Tenax Therapeutics; Esperion Therapeutics; Alnylam Pharmaceuticals; Novo Nordisk; MyoKardia; Gilead Sciences; Eisai; Cytokinetics; Brigham and Women's Hospital","keywords":"Dapagliflozin; Ejection fraction; Medicine; Placebo; Heart failure; Internal medicine; Cardiology; Heart failure with preserved ejection fraction; Randomized controlled trial; Atrial fibrillation; Diabetes mellitus; Type 2 diabetes; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01893109,0.002628661,0.01084395,0.001776057,0.0003233902,0.002297686,0.001049952,0.001507136,0.003863648],"category_scores_gemma":[0.02222819,0.001052774,0.02372778,0.002133246,0.0005456491,0.001268235,0.001572682,0.00152214,0.0003826233],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006456733,"about_ca_system_score_gemma":0.0007002465,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001235733,"about_ca_topic_score_gemma":0.002711993,"domain_scores_codex":[0.9844083,0.009177878,0.002678223,0.002051607,0.00118392,0.000500009],"domain_scores_gemma":[0.9859214,0.007370486,0.003549723,0.001873184,0.0009078329,0.0003774426],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"meta_analysis","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.151279,0.0001401868,0.02190747,0.01394513,0.7938373,0.0001093786,0.00006509935,0.001610096,0.0009118842,0.0001301874,0.00182425,0.01424001],"study_design_scores_gemma":[0.08001913,0.005280178,0.07794689,0.000905882,0.8305639,0.0002065678,0.00006577246,0.001266579,0.0004206374,0.0005897082,0.002635429,0.00009942964],"study_design_candidate":"meta_analysis","study_design_consensus":"meta_analysis","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5868564,0.3662856,0.01040676,0.001107849,0.001106572,0.002820077,0.0262822,0.0005959008,0.004538569],"genre_scores_gemma":[0.9721072,0.01524702,0.002405229,0.0007772744,0.0004985945,0.001435846,0.00685429,0.00007381224,0.0006005859],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01893109,"threshold_uncertainty_score":0.1001184,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0516322117843698,"score_gpt":0.3040859879546243,"score_spread":0.2524537761702545,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}